All News

Losing even 5% of body weight can improve comorbid conditions and other health complications for individuals with overweight and obesity.

Shivang Joshi, MD, MPH, RPh, FAHS discusses how pharmacists can utilize their role as the most accessible health care professional to provide care to patients with migraine, as well as resources to enhance awareness and education.

Shivang Joshi, MD, MPH, RPh, FAHS, headache specialist neurologist at Community Neuroscience Services, debunks common migraine myths.

Patrick Alonso, PharmD, CPh, discusses how pharmacists' skills are underutilized and how they can help support men’s health.

Patrick Alonso, PharmD, CPh, provides some tips for men looking to improve their overall mental health.

Patrick Alonso, PharmD, CPh, discusses how pharmacists can support men dealing with mental health issues and lifestyle changes he recommends to male patients to improve overall health.

Patrick Alonso, PharmD, CPh, owner and manager of BlueZone Health Care Advocates and co-host of the Men’s Health Unscripted podcast, talks about how health care providers can build trust with male patients and what screenings men at different ages should be having.

Sam Clark, MD, PhD, founder and CEO of Terran Biosciences, discusses how some of the concern’s raised by the panel can inform future psychedelic research.

Sam Clark, MD, PhD, founder and CEO of Terran Biosciences, talks about some of the problems he saw during the Psychopharmacologic Drugs Advisory Committee meeting.

Savannah Roberts Clary, PharmD, BCPS, CPGx, a clinical pharmacist with Aegis Sciences Corporation, talks about the dangers of tianeptine and how pharmacists can help warn the public about the potential hazards of tianeptine.

Pharmacists must take a multifaceted approach to educating patients on sun safety that extends beyond sunscreen counseling, according to Colleen McCabe, PharmD, BCOP.

Colleen McCabe, PharmD, BCOP, emphasizes the importance of a proactive and tailored approach for pharmacists educating patients on skin cancer risks specific to their communities.

The market is sensitive to both upstream and downstream pressures that impact drug pricing.

The specialty drug market has exploded, and will continue to grow across sectors such as oncology and neurology.

A lack of clarity around certain provisions of the Inflation Reduction Act has presented challenges to payers.

Understanding the goals of each party is the first step to a successful collaboration.

Collaboration between health system specialty pharmacists and pharmaceutical manufacturers can benefit patients in the long run.

Addressing requirements around FDA interchangeability designations can increase the adoption of biosimilar substitutions at the pharmacy level.

A recent bill introduced to Congress is intended to prevent product hopping, a practice that extends exclusivity and hinders the adoption of biosimilar therapies.

Distributors can help manufacturers create patient access programs that reduce costs, copays, and co-insurance.

One notable incentive includes the launch of biosimilars at both low- and high wholesale acquisition costs.

Pharmacists can help financial decision makers understand the value of biosimilar therapies.

Savings associated with biosimilar uptake are projected to reach $181 billion through 2027.

The expertise of health system specialty pharmacists, combined with better adherence and better affordability, leads to better patient outcomes.

Paying for these new therapies, that may be curative for patients, remains a challenge.

From medication adherence to patient counseling, clinical pharmacists at health system specialty pharmacies can play a role in reducing health care costs.

According to Scott Soefje, PharmD, understanding nuances across sites of care can help health care providers optimize patient care delivery while ensuring financial viability across all settings.

Karen Fancher, PharmD, addresses how hearing the perspectives of colleagues can offer invaluable support to shape individualized approaches to ethical dilemmas in oncology pharmacy.

While prioritizing either cost or margin may be necessary at a site of care, big picture items, such as societal responsibility and long-term health care affordability, should guide financial analyses, said Scott Soefje, PharmD.

According to Kirollos Hanna, PharmD, although similarities exist between bispecific therapies in the myeloma space, health care providers should take special note of practical differences and nuances associated with each when operationalizing them at their site of care.